Invokana is the Most Advertised Drug in Professional Health Journals through Q1 2014

by Client Services

Invokana, which launched in 2013 and treats type 2 Diabetes, is the top drug advertised in medical journals by both pages and dollars through Q1 2014, according to Kantar Media. Fetzima, a recently-launched drug, currently ranks second. Many of the products in the top ten launched in this year

Top 5 Print Ad Drugs (Dollars): March 2014

#1 Invokana – $6 MM (+9,251%)

#2 Fetzima – $4 MM (N/A)

#3 Brintellix Tablets - $3 MM (N/A)

#4 Belviq (Lorcaserin HCI) IV - $2 MM (N/A)

#5 Xarelto – $2 MM (-57%)

The percentage changes compare March 2014 to that same time period in 2013. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.